Cross-Sector entity
Keytruda is the most frequent co-covered peer, appearing in 5 of the 20 tracked stories. The 151-day window averages about 0.9 stories each week. The busiest single day carried 5. The clearest coverage concentration is pharma: 6 of 20 stories, with the rest divided among 7 other categories.
25 verified stories tracked
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 45 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Keytruda is the most frequent co-covered peer, appearing in 5 of the 20 tracked stories. The 151-day window averages about 0.9 stories each week. The busiest single day carried 5. The clearest coverage concentration is pharma: 6 of 20 stories, with the rest divided among 7 other categories. Each carries 3.1 original sources on average. Negative sentiment appears in 10% of the tracked stories. Novartis appears in 20 tracked Cross-Sector stories published from February 27, 2026 through July 27, 2026.
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Novartis. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Expiry
Merck faces biosimilar competition for its top-selling immunotherapy drug.
TERN-701 Data Readout
Key clinical milestones for the leukemia candidate are expected to drive valuation.
Interim Analysis
Expected interim efficacy data from the larger global patient cohort.
Data Review
Expected first quarterly report on screening uptake and identification rates in Scotland.
Part 2 Expansion
Full global enrollment for efficacy endpoints (rPFS and OS) expected to accelerate.
Expected Closing
The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
Acquisition Announced
Merck and Terns Pharmaceuticals sign a definitive agreement for a $6.7B buyout.
Official Rollout
Scotland officially begins screening all newborns for the rare muscle disease.
Q4 2025 Earnings
Reported year-end financial results and updated 2027 cash runway.
Expected Rebalancing
Passive funds expected to complete divestment of RNAM shares to match new index weights.
Primary Objectives Met
Announcement that Part 1 successfully validated safety and dosimetry profiles.
FY 2025 Earnings
Legend Biotech reports full-year financial results and 2026 strategic outlook.
Earnings Previews
Seeking Alpha releases Q4 2025 previews for both Voyager and Zevra.
CFO Appointment
Zevra Therapeutics names Justin Renz as Chief Financial Officer.
S&P Index Deletion
S&P Dow Jones Indices removes RNAM from Global BMI and TMI benchmarks.
Q4 2025 Earnings
Both companies report full-year 2025 results and 2026 guidance.
Scotland Launch
Scotland officially begins nationwide screening for all newborns.
Novartis Settlement
Novartis announces a confidential settlement with the Henrietta Lacks estate.
Novartis Deal Closure
Avidity finalizes agreement with Novartis, launching Atrium Therapeutics spinout.
Anticipated Milestone
Expected Phase 1 data readout for MRT-6160 in autoimmune diseases.
A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Source: prnewswire.com · finanznachrichten.de
Two of Australia’s most used MS therapies, Ocrevus and Kesimpta, face a PBS pricing review that could slash subsidies by 40–50%. Without coverage, patients could pay over $33,000 annually, jeopardizing treatment access for thousands.
A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.
Source: maitlandmercury.com.au · ulladullatimes.com.au
Hundyai’s audio campaign, The Ordinary’s dystopian film, and Novartis’ 'Relax Your Tight End' won top honors at Cannes Lions 2026, signaling a creative shift for marketers. These victories highlight the power of sonic branding, narrative depth, and humor in health communication as key drivers of audience engagement.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion, securing a late-stage leukemia candidate to diversify its oncology portfolio. The deal provides Merck with TERN-701, a promising treatment for chronic myeloid leukemia, as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for Spinal Muscular Atrophy (SMA). This landmark public health initiative aims to identify the rare genetic condition within days of birth, enabling immediate access to life-saving gene therapies before irreversible muscle wasting occurs.
Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for a rare genetic muscle disease. This landmark policy shift aims to identify affected infants at birth, allowing for immediate intervention and treatment before the onset of irreversible physical symptoms.
Source: lancashiretelegraph.co.uk · echo-news.co.uk
Monte Rosa Therapeutics reported quarterly results highlighting a robust cash position following its $2.1 billion Novartis partnership. The company is accelerating its molecular glue degrader pipeline with a strategic pivot toward high-value immunology indications.
Source: themarketsdaily.com · tickerreport.com
Legend Biotech (LEGN) has released its full-year 2025 financial results, showcasing significant revenue growth driven by the continued commercial expansion of its lead CAR-T therapy, Carvykti. The company highlighted major manufacturing milestones and a strategic pivot toward solid tumor indications following a year of intensive market penetration in earlier lines of multiple myeloma treatment.
Source: manilatimes.net · manilatimes.net
Telix Pharmaceuticals has announced that Part 1 of its ProstACT GLOBAL Phase 3 study for TLX591 successfully met its primary objectives. This milestone confirms the safety and dosimetry of the company's lead radiopharmaceutical candidate for metastatic prostate cancer, clearing the way for full trial expansion.
Telix Pharmaceuticals has successfully met the primary objectives for Part 1 of its global Phase 3 ProstACT study, validating the safety and dosimetry of its lead therapeutic candidate, TLX591. This milestone de-risks the antibody-based radiopharmaceutical program and clears the path for the trial's continued expansion in metastatic castration-resistant prostate cancer.
Source: sydneysun.com · wallstreet-online.de
Voyager Technologies and Zevra Therapeutics are set to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution and platform validation. Investors are focused on Zevra's Miplyffa launch trajectory and Voyager's CNS-focused partnership revenue.
Voyager Technologies and Zevra Therapeutics are preparing to report Q4 2025 results, highlighting a pivotal period for gene therapy platforms and rare disease commercialization. Investors are focused on Voyager's partnership revenue and Zevra's initial market traction for its newly approved NPC treatment.
Voyager Technologies and Zevra Therapeutics are set to report Q4 2025 earnings, highlighting a critical juncture for gene therapy delivery and rare disease commercialization. Investors are prioritizing updates on the TRACER platform milestones and the market penetration of newly launched orphan drugs.
Source: Seeking Alpha · Seeking Alpha
Avidity Biosciences (RNAM) has been removed from the S&P Global BMI and S&P TMI indices, effective March 2026. This technical deletion follows a major strategic milestone involving a deal closure with Novartis, signaling a period of significant structural transition for the biotech firm.
Novartis has reached a confidential settlement with the estate of Henrietta Lacks, ending litigation over the unauthorized use of her 'immortal' HeLa cells. This marks the latest in a series of legal victories for the Lacks family against pharmaceutical giants that profited from cells taken without consent in 1951.
